Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts [4]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 5, 2007, Pages 600-601

  Nieuwkerk, Pythia T ^a   Hillebrand Haverkort, Milly E ^b   Vriesendorp, Robert ^c   Frissen, P H Jos ^d   De Wolf, Frank ^a,e   Sprangers, Mirjam A G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Medical Centre Alkmaar   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e STICHTING HIV MONITORING   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NETHERLANDS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; NETHERLANDS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34548068517     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318074efbf     Document Type: Letter

References (10)

1. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiation triple-drug therapy. JAMA. 2001;286:2568-2577.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
3. Palella FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.
4. 6/L. AIDS. 2002;16:1371-1381.
5. Cohen C, Revicki DA, Nabulsi A, et al. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS. 1998;12:1495-1502.
6. Murri R, Ammassari A, Fantoni M, et al. Disease-related factors associated with health-related quality of life in peoplewith nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:350-356.
7. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. ATHENA Cohort Study Group. AIDS. 2003;17:2227-2236.
8. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care. 1991;29:786-798.
9. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care. 1998;36:126-137.
10. Locadia M, van Grieken RA, Prins JM, et al. Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection. Antivir Ther. 2006;11:335-341.